home / stock / mrus / mrus news

MRUS News and Press, Merus N.V. From 05/20/19

Stock Information
Company Name: Merus N.V.
Stock Symbol: MRUS
Market: NASDAQ
Website: merus.nl
Menu
MRUS MRUS Quote MRUS Short MRUS News MRUS Articles MRUS Message Board
Get MRUS Alerts

News, Short Squeeze, Breakout and More Instantly...
MRUS - Merus to Present at the RBC Capital Markets 2019 Healthcare Conference

UTRECHT, Netherlands, May 20, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibod...
MRUS - Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors

UTRECHT, Netherlands, May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial ...

MRUS - Merus reports Q4 results

Merus (NASDAQ: MRUS ): Q4 GAAP EPS of -€0.02. More news on: Merus N.V., Earnings news and commentary, Healthcare stocks news, Read more ...

MRUS - Merus Announces Financial Results for the Full Year 2018 and Provides Business Update

Multiple Updates from Biclonics® Clinical Trials Expected in 2019 UTRECHT, The Netherlands, April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology com...
MRUS - Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019

CD137 and PD-L1 bispecific antibody with context-dependent T cell activation UTRECHT, Netherlands, April 01, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology c...

MRUS - Merus (MRUS) Investor Presentation - Slideshow

The following slide deck was published by Merus N.V. in conjunction with this Read more ...

MRUS - IBI Research On Merus: Elucidating The Prospects Of An Antibody Innovator

I remember my sense of shock some half-dozen years ago when I read a recommendation to sell shares of a company. The recommendation was not based on any long-term fundamentals. Rather, it was that over the next six months the funds could be employed more profitably elsewhere. - Phillip Fisher...
MRUS - Merus to Present at the Cowen & Co. 39th Annual Health Care Conference

UTRECHT, Netherlands, March 11, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific an...

MRUS - Merus to Participate in Guggenheim Healthcare Talks Idea Forum

UTRECHT, Netherlands, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that Mark Throsby, Ph.D., Executive Vice President and Chief Sc...

MRUS - Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up...
Previous 10 Next 10